Serono's multiple sclerosis drug Rebif, which had sales of more than $1 billion last year, may be the biggest attraction for potential buyers of Europe's largest biotech company. Serono confirmed it has hired Goldman Sachs to explore strategies but said a sale is not a certainty. The Wall Street Journal reports Novartis, Pfizer and GlaxoSmithKline have been in talks with Serono about a possible takeover, which could include a $15 billion price tag.

Related Summaries